

INVITATION TO ALLIGATOR BIOSCIENCE'S INTERIM REPORT CALL ON 22 OCTOBER 2026

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for July – September 2026 on Thursday, 22 October 2026, at 8:00 a.m. CEST.

On the same day, Alligator will host a webinar and conference call for investors, analysts and media at 2:00 p.m. CEST / 8:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report. The presentation will be followed by a Q&A session.

The call will be held in English. Attendees are required to register in advance via [this link](#) and are welcome to submit questions in advance to ir@alligatorbioscience.com.

The full report will be available upon publication [on Alligator's website](#).

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

Johan Giléus, CFO

E-mail: johan.gileus@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

The information was submitted for publication, through the agency of the contact persons set out above, at 2:00 p.m. CEST on 15 October 2026.

About Alligator Bioscience

Alligator is a biotechnology company that has historically focused on tumor-directed immuno-oncology. Following a strategic refocus, Alligator is prioritizing the value of its economic interest in HLX22, an anti-HER2 monoclonal antibody being developed by Shanghai Henlius Biotech Inc., from which Alligator is entitled to a share of revenues without incurring development costs. Alligator has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset in the near term.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

PRESS RELEASE

15 October 2026 14:00:00 CEST



For more information, please visit alligatorbioscience.com.

Attachments

Invitation to Alligator Bioscience's interim report call on 22 October 2026